Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial

被引：5
|
作者：
Briones, Javier [1 ]
Novelli, Silvana [1 ]
Garcia-Marco, Jose A. [2 ]
Tomas, Jose F. [3 ]
Bernal, Teresa [4 ]
Grande, Carlos [5 ]
Canales, Miguel A. [6 ]
Torres, Antonio [7 ]
Moraleda, Jose M. [8 ]
Panizo, Carlos [9 ]
Jarque, Isidro [10 ]
Palmero, Francisca [11 ]
Hernandez, Miguel [12 ]
Gonzalez-Barca, Eva [13 ]
Lopez, Dulce [1 ]
Caballero, Dolores [14 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp Univ Puerta de Hierro, Madrid, Spain
[3] MD Anderson Int, Madrid, Spain
[4] Hosp Univ Cent Asturias, Oviedo, Spain
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Hosp La Paz, Madrid, Spain
[7] Hosp Reina Sofia, Cordoba, Spain
[8] Hosp Virgen Arrixaca, Murcia, Spain
[9] Univ Navarra Clin, Pamplona, Spain
[10] Hosp Univ La Fe, Valencia, Spain
[11] Hosp Univ Alicante, Alicante, Spain
[12] Hosp Univ Canarias, Tenerife, Spain
[13] ICO Duran & Reynals, Barcelona, Spain
[14] Hosp Univ Salamanca, Salamanca, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷 / 07期
关键词：
diffuse large B-cell lymphoma; ibritumomab tiuxetan; autologous transplantation; relapse;
D O I：
10.3324/haematol.2014.108308
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes after 90Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
    Auger-Quittet, Sophie
    Duny, Yohan
    Daures, Jean-Pierre
    Quittet, Philipe
    CANCER MEDICINE, 2014, 3 (04): : 927 - 938
  • [42] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [43] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Palumbo, B.
    Sabalich, I.
    Falcinelli, F.
    Capponi, M.
    Martelli, M.
    Palumbo, R.
    Sinzinger, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [44] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
  • [45] SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN HIGH-RISK AGGRESSIVE B CELL NON-HODGKIN'S LYMPHOMA AFTER 90YTTRIUM IBRITUMOMAB TIUXETAN-BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
    Wondergem, M.
    De Rooij, M.
    Zijlstra, J.
    Ossenkoppele, G.
    Huijgens, P.
    ANNALS OF ONCOLOGY, 2011, 22 : 170 - 170
  • [46] 90YTTRIUM IBRITUMOMAB TIUXETAN (ZEVALIN) COMBINED WITH BEAM (Z-BEAM) CONDITIONING REGIMEN PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. A GELA PHASE II PROSPECTIVE STUDY
    Gisselbrecht, C.
    Decaudin, D.
    Mounier, N.
    Tilly, H.
    Ribrag, V.
    Sebban, C.
    Milpied, N.
    Morschhauser, F.
    Coiffier, B.
    Le Gouill, S.
    Lederlin, P.
    Delarue, R.
    Laurent, G.
    Bosly, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 418 - 418
  • [47] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Kim, Moon Jin
    Lee, Gyeong-Won
    Seo, Jong Woo
    Kim, Hyun-Jung
    Lim, Sung-Nam
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1098 - 1101
  • [48] Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).
    Khouri, Issa F.
    Saliba, Rima M.
    Hosing, Chitra
    Valverde, Rosamar
    Erwin, William D.
    Fayad, Luis
    Maadani, Farzaneh
    Korbling, Martin J.
    Okoroji, Grace-Julia
    Stachowiak, Anne M.
    Samuels, Barry I.
    Anderlini, Paolo
    Couriel, Daniel R.
    de Lima, Marcos
    Giralt, Sergio
    Popat, Uday
    Kebriaei, Partow
    Ueno, Naoto T.
    Qazilbash, Muzaffar H.
    McLaughlin, Peter W.
    Hagemeister, Fredrick B.
    Younes, Anas
    Podoloff, Donald A.
    Champlin, Richard E.
    BLOOD, 2006, 108 (11) : 98A - 98A
  • [49] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in the treatment of non-Hodgkin's lymphoma (NHL):: Incorporation into autologous stem cell transplantation (ASCT) regimens
    Nademanee, A
    Krishnan, A
    Fung, H
    Raubitschek, A
    Forman, S
    Molina, A
    ANNALS OF ONCOLOGY, 2005, 16 : 100 - 100
  • [50] Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Hasenkamp, Justin
    Hess, Georg
    Hertenstein, Bernd
    Dreger, Peter
    Uharek, Lutz
    Gramatzki, Martin
    Schubert, Joerg
    Wulf, Gerald
    Truemper, Lorenz
    Schmitz, Norbert
    Glass, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345